Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus CLAFORAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus CLAFORAN.
CEFTAZIDIME IN DEXTROSE CONTAINER vs CLAFORAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
Cefotaxime is a bactericidal cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
1-2 g intravenously every 8 hours.
1-2 g IV/IM every 8 hours. Maximum dose: 12 g/day in divided doses.
None Documented
None Documented
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
0.8-1.4 hours in normal renal function (prolonged to 11-30 hours in severe renal impairment, CrCl <10 mL/min). No clinically relevant accumulation with standard dosing in renal impairment with dose adjustment.
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Primarily renal (80-90% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic